CD14 and melanoma: Our finding that CD14+CD16neg classical monocytes showed a negative association with obesity is of interest, due to a prior report by Krieg et al., who found that in stage IV melanoma patients, increased frequencies of circulating CD14+CD16negHLA-DRhigh monocytes prior to anti-PD-1 therapy predicted improved treatment outcomes [25].